TIME IS RUNNING OUT FOR CONGRESS TO APPROVE MEDICARE COVERAGE FOR A SIMPLE BLOOD TEST THAT CAN HELP DETECT CANCER IN EARLIER, MORE TREATABLE STAGES. ADVOCATES TONIGHT SAY WITHOUT MEDICARE COVERAGE, ...
It's the first and one of the hardest tests of the Democrats' ambitious plan to overhaul the nation's health care system: establishing a federally funded program in the next 90 days to cover people ...
(Reuters) - Guardant Health said its blood test to detect cancer that starts in the colon or rectum got an approval from the U.S. Food and Drug Administration, with the test moving closer toward ...
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...
Cancer test maker Lucid Diagnostics (NASDAQ:LUCD), majority owned by PavMed (NASDAQ:PAVM), traded ~8% lower on Wednesday after the company said that a group of medical experts will meet in September ...
Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data ...
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it has received new commercial health plan coverage for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results